| | Treatment efficacy | Appearance | Financial impact | Visit Duration | Productivity |
| n responded | 355 | 347 | 350 | 356 | 353 |
| n (%) important | 243 (68.5) | 144 (41.5) | 148 (42.3) | 118 (33.1) | 133 (37.7) |
| | Odds ratio (95% Confidence Interval) |
| Age | | | | | |
| ≤50 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| >50 | 1.78 (1.03, 3.05)† | 1.22 (0.72, 2.05) | 0.47 (0.28, 0.78)‡ | 2.16 (1.26, 3.71)‡ | 0.84 (0.50, 1.43) |
| Gender | | | | | |
| Male | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Female | 2.07 (1.27, 3.36)‡ | 1.98 (1.23, 3.19)‡ | 1.18 (0.74, 1.9) | 1.06 (0.65, 1.72) | 1.50 (0.93, 2.40) |
| Race | | | | | |
| White | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Non-White | 1.77 (0.88, 3.56) | 1.82 (0.98, 3.36) | 2.80 (1.49, 5.29)‡ | 2.60 (1.41, 4.78)‡ | 1.67 (0.91, 3.04) |
| Insurance | | | | | |
| Private | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Public/self-pay | 2.11 (1.20, 3.68)‡ | 0.91 (0.54, 1.51) | 1.07 (0.64, 1.81) | 1.37 (0.82, 2.28) | 2.24 (1.35, 3.71)‡ |
| History of skin cancer | | | | | |
| Yes | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| No | 1.03 (0.59, 1.80) | 2.71 (1.56, 4.73)‡ | 1.92 (1.11, 3.32)† | 2.34 (1.33, 4.14)‡ | 1.32 (0.77, 2.26) |
|
|